Payment overview · 2025
General Payments
$1,631.32
99 reported records · 22 companies
Healthcare provider profile · identity verified
Caroline B Stevens, DO
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ANDERSON, IN · NPI 1992028039
Verified facts
What the public records show
CMS Open Payments records show Caroline B Stevens, DO received $1,631.32 in general payments during 2025 across 99 reported records.
ABBVIE INC. accounted for 37.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid, Nurtec Odt, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Nuplazid by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rexulti by this doctor in 2024.
MDD US Operations, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gocovri as an associated drug or biological on 3202 records involving 1029 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gocovri by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Mayzent by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $603.13 | 37.0% | 43 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $110.40 | 6.8% | 6 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $96.32 | 5.9% | 6 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $83.19 | 5.1% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $79.52 | 4.9% | 5 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $75.62 | 4.6% | 4 | 2025 |
| CATALYST PHARMACEUTICALS, INC. | Unresolved — no canonical attribution shown | $70.16 | 4.3% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $67.98 | 4.2% | 4 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$57.82 | 3.5% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$54.34 | 3.3% | 1 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $53.42 | 3.3% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $51.22 | 3.1% | 3 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $38.65 | 2.4% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $33.19 | 2.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $32.10 | 2.0% | 2 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $23.84 | 1.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.15 | 1.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $18.14 | 1.1% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $17.13 | 1.1% | 1 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $16.46 | 1.0% | 1 | 2025 |
| Tanabe Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.79 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.75 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,631.32 | 99 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $227.88 | 22 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $225.20 | 10 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $218.78 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $152.56 | 17 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $110.40 | 6 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $96.32 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $79.52 | 5 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $75.62 | 4 | 2025 |
Source payment records
|
|||||
| FYCOMPA Normalized: fycompa |
Drug | CATALYST PHARMACEUTICALS, INC. | $70.16 | 3 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $67.98 | 4 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $66.27 | 4 | 2025 |
Source payment records
|
|||||
| SENSIGHT Normalized: sensight |
Device | Medtronic, Inc. | $54.34 | 1 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $53.42 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $50.56 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $37.33 | 2 | 2025 |
Source payment records
|
|||||
| INFINITY Normalized: infinity |
Device | Abbott Laboratories | $32.10 | 2 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $21.54 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $17.13 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $17.11 | 1 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| Radicava Normalized: radicava |
Drug | Tanabe Pharma America, Inc. | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| EMGALITY Normalized: emgality |
Drug | Lilly USA, LLC | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $13.89 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 67 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| MDD US Operations, LLC Exact reporting entity; no affiliate inference |
2025 | Gocovri open payments reported associated product |
CMS Open Payments — General Payments 3202 supporting records · 1029 recipient NPIs · example record 1241843637 |
Gocovri · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
67 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 261 | 63 |
| Gabapentin | Gabapentin | 205 | 55 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 195 | 43 |
| Levetiracetam | Levetiracetam | 175 | 38 |
| Topiramate | Topiramate | 164 | 40 |
| Primidone | Primidone | 147 | 40 |
| Memantine Hcl | Memantine Hcl | 131 | 32 |
| Sertraline Hcl | Sertraline Hcl | 91 | 34 |
| Ropinirole Hcl | Ropinirole Hcl | 89 | 24 |
| Atorvastatin Calcium | Atorvastatin Calcium | 78 | 28 |
| Pregabalin | Pregabalin | 68 | 15 |
| Nurtec Odt | Rimegepant Sulfate | 67 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 61 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 60 | 19 |
| Lacosamide | Lacosamide | 55 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 50 | suppressed |
| Baclofen | Baclofen | 49 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 43 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 42 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 41 | 14 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 39 | suppressed |
| Mirtazapine | Mirtazapine | 39 | 11 |
| Amantadine | Amantadine Hcl | 37 | 15 |
| Carbamazepine Er | Carbamazepine | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 37 | 11 |
| Aptiom | Eslicarbazepine Acetate | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | 11 |
| Zonisamide | Zonisamide | 34 | 11 |
| Ondansetron Odt | Ondansetron | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | 11 |
| Ubrelvy | Ubrogepant | 26 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 23 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 23 | suppressed |
| Diazepam | Diazepam | 22 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Selegiline Hcl | Selegiline Hcl | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Levetiracetam Er | Levetiracetam | 21 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 21 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 21 | suppressed |
| Teriflunomide | Teriflunomide | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Fingolimod | Fingolimod Hcl | 20 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Acetazolamide Er | Acetazolamide | 17 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Mayzent | Siponimod | 15 | suppressed |
| Rufinamide | Rufinamide | 15 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Copaxone | Glatiramer Acetate | 13 | suppressed |
| Eliquis | Apixaban | 13 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 13 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 13 | suppressed |
| Nourianz | Istradefylline | 12 | suppressed |
| Gocovri | Amantadine Hcl | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Pimozide | Pimozide | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Topiramate Er | Topiramate | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,631.32 · 99 records | ABBVIE INC. | AUSTEDO XR, Apokyn, BOTOX, BRIUMVI, CREXONT, EMGALITY, FYCOMPA, INBRIJA, INFINITY, KESIMPTA, NUPLAZID, NURTEC ODT, Nayzilam, QULIPTA, Radicava, Rystiggo, SENSIGHT, Sunosi, Symbravo, TYSABRI, UBRELVY, ULTOMIRIS, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, WAKIX, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error